First-line therapy in relapsing remitting multiple sclerosis.

Biotti, D; Ciron, J

Biotti, D; Ciron, J.

Affiliation

Biotti D; Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France. Electronic address: biotti.d@chu-toulouse.fr.
Ciron J; Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France.

Rev Neurol (Paris) ; 174(6): 419-428, 2018 Jun.

Article in En | MEDLINE | ID: mdl-29703445

Subject(s)

Immunologic Factors/administration & dosage; Immunosuppressive Agents/administration & dosage; Multiple Sclerosis, Relapsing-Remitting/therapy; Drug Administration Routes; Drug Administration Schedule; France; Humans; Immunologic Factors/adverse effects; Immunosuppressive Agents/adverse effects; Quality of Life; Treatment Outcome

Key words

Fumarates; Glatiramer acetate; Interferon; Multiple sclerosis; Teriflunomide; Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Immunologic Factors / Immunosuppressive Agents Limits: Humans Country/Region as subject: Europa Language: En Journal: Rev Neurol (Paris) Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google